Cramer's Morning Take: Eli Lilly & Novo Nordisk 1/24/25

The discussion dives into the competitive landscape of weight loss drugs, spotlighting Eli Lilly and Novo Nordisk. It highlights Novo Nordisk's promising trial results and compares the effectiveness of their medications. Additionally, there’s a focus on Eli Lilly’s rebound, marked by increasing prescription growth after a slow performance last quarter. Insights into Lilly's new developments, including an emerging amylin molecule, add depth to the conversation.